Barrow, CloudMedx to Use AI to Better Understand ALS Progression
The Gregory W. Fulton ALS and Neuromuscular Disease Center at Barrow is collaborating with a healthcare artificial intelligence (AI) company to track disease progression in people with amyotrophic lateral sclerosis (ALS).
Currently, little is known about the disease progression, which varies greatly from patient to patient, and treatments are subjective.
CloudMedx will use data from medical records to identify better predictors of disease progression and survival. Dr. Shafeeq Ladha, director of the ALS Center, and his team hope the AI approach will help speed therapy development and allow them to provide ALS patients with more personalized treatments.